EUROBIO SCIENTIFIC: CONCLUSION OF AN AGREEMENT BETWEEN EUROBIO SCIENTIFIC AND A CONSORTIUM LED BY EUROBIO SCIENTIFIC’S TEAM OF ENTREPRENEURS AND MANAGERS, IK PARTNERS AND NEXTSTAGE AM WITH A VIEW TO FILE A VOLUNTARY TENDER OFFER AT A PRICE

NOT FOR DISTRIBUTION, PUBLICATION OR RELEASE, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN THE UNITED STATES OR TO ANY US PERSON, OR TO ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION, PUBLICATION OR RELEASE WOULD BE UNLAWFUL.

CONCLUSION OF AN AGREEMENT BETWEEN EUROBIO SCIENTIFIC AND A CONSORTIUM LED BY EUROBIO SCIENTIFIC’S TEAM OF ENTREPRENEURS AND MANAGERS, IK PARTNERS AND NEXTSTAGE AM WITH A VIEW TO FILE A VOLUNTARY TENDER OFFER AT A PRICE OF €25.30 PER EUROBIO SCIENTIFIC SHARE

• The Offer Price represents a premium of 67.5 % over the volume-weighted average share price over 60 trading days¹and of 39 % over the last closing price of Eurobio Scientific shares prior to the announcement of the Offer
• The Board of Directors of Eurobio Scientific:
  • has unanimously approved the principle of the proposed transaction in accordance with the recommendations of the ad hoc committee, without prejudice to the review of the contractual documentation and the Offer documentation to be carried out by the independent expert
  • will meet at a later date to issue a reasoned opinion on the Offer after consultation with the Company’s social and economic committee (“CSE”) and receipt of the independent expert’s report
• An ad hoc committee, comprising a majority of independent directors and chaired by one of them, supervises the work of Ledouble SAS, which has been chosen as the independent expert
• The Offer is expected to be filed at the end of September with the AMF (French financial markets authority) and will be subject to the prior approval of the competent merger control and foreign investment control authorities in France and Italy.

Paris, July 31^st, 2024, 9:00 pm

Eurobio Scientific (FR0013240934, ALERS), a leading French group in the field of specialty in vitro medical diagnostics (the “Company“), announces that funds managed by NextStage AM and IK Partners, together with Mr. Denis Fortier, CEO, and other members of the Company’s Board of Directors and senior management², have decided to form a consortium (the “Consortium“) in order to launch a voluntary tender offer for all of the outstanding Eurobio Scientific shares (the “Offer“), which may be followed, if the conditions are met, by a squeeze-out.

The Company’s Board of Directors, which met on July 31^st 2024, approved the principle of the proposed transaction, which would accelerate Eurobio Scientific’s organic and inorganic growth plan. The Offer, which would enable the Company’s shareholders to benefit from a significant and immediate liquidity opportunity, will be made at a price of 25.30 euros per Eurobio Scientific share (the “Offer Price“), which represents a premium of 39 % over its last closing price prior to the announcement of the Offer and of 67.5 % over its volume-weighted average price over 60 trading days.

The Board also authorised the conclusion of a cooperation agreement in connection with the Offer between the Company and EB Development SAS, a company indirectly wholly-owned by funds managed by IK Partners and intended to be jointly owned, directly or indirectly, by the members of the Consortium (the “Bidder“), if the Offer is successful.

An important step in securing the Company’s development

The Company’s ambition is to pursue its development in the fields of infectious diseases, transplantation and oncology. The Company realized that the listing of its shares did not provide the flexibility theoretically offered by the stock market for its financing, and that it did not have the financial resources to support its development. Furthermore, in an environment that penalises mid caps, the cost and constraints associated with the listing seem less and less justified. The objective of the proposed Offer is to back the Company with a new institutional partner, IK Partners, a leading European private equity firm with the resources and support of a large international organisation, to meet its needs. The members of the Consortium recognize the Group’s positioning in the field of in vitro diagnostics and life sciences, and are convinced that going private would provide a better environment for development.

The proposed Offer meets all of the Company’s strategic objectives and would enable it to pursue its development plan with a shareholder base that actively supports its strategy.

The Board of Directors of Eurobio Scientific approves the Offer pending the opinion of the CSE and the conclusions of the independent expert.

Following the recommendation of its ad hoc committee composed of Mr. Patrick de Roquemaurel (chairman of the committee and independent director), Mr. Michel Picot (independent director) and Mr. Hervé Duchesne de Lamotte, the Board of Directors of the Company, which met on July 31^st, 2024, expressed a positive preliminary opinion under the terms of which the directors unanimously and favourably approved the principle of the Offer, it being specified that this opinion will be reviewed in accordance with the detailed study of the terms and conditions of the draft Offer and the report to be drawn up by the independent expert.

This decision was taken unanimously by the directors, it being specified that, having declared, prior to the Board meeting, the potential conflict of interest in which they find themselves as a result of the conclusion of an Investment Agreement with the other members of the Consortium, Ms. Catherine Courboillet, Mr. Denis Fortier, Mr. Jean-Michel Carle-Grandmougin, Mr. Hervé Duchesne de Lamotte and EurobioNext, represented by Mr. Grégoire Sentilhes, directors who are also members of the Consortium, undertook to vote in accordance with the recommendation of the ad hoc committee in order to avoid any potential conflict of interest and to ensure that the quorum and majority required for the validity of the decision of the Company’s Board of Directors were met.

On the proposal of the ad hoc committee, and in accordance with the provisions of Article 261-1 of the General Regulation of the Autorité des marchés financiers (French financial markets authority, or the “AMF“), the Board of Directors has confirmed Ledouble, represented by Olivier Cretté (8, rue Halévy – 75009 Paris +33 (0)1 43 12 57 16 – ocrette@ledouble.fr), as the independent expert responsible for issuing a report on the financial terms of the Offer (including the possible implementation of a squeeze-out procedure), and the absence of related agreements likely to affect the equal treatment of shareholders. The conclusion of the report will take the form of a fairness opinion.

The Board of Directors has also decided to initiate today an information-consultation procedure with the CSE.

After considering the opinion of the CSE and the report of the independent expert, the Board of Directors of the Company will issue, on the prior recommendation of its ad hoc committee, a reasoned opinion on the Offer and its consequences for the Company, its shareholders and its employees.

The reasoned opinion of the Board of Directors, together with the report of the independent expert, will be appended to the final reply document prepared by the Company and approved by the AMF.

Cooperation agreement between the Company and EB Development SAS

The cooperation agreement for the Offer between the Company and the Bidder was authorised by the Board of Directors on July 31^st, 2024, in accordance with the procedure for regulated agreements. Mr. Denis Fortier, Mr. Jean-Michel Carle-Grandmougin, Mr. Hervé Duchesne de Lamotte, Ms. Catherine Courboillet and EurobioNext, represented by Mr. Grégoire Sentilhes, directors and members of the Consortium, did not take part in the decision.

Under the terms of this agreement, the Company, in particular:

• undertook not to tender its treasury shares (i.e., to date, 206,743 shares in the Company) to the Offer;
• undertook to refrain from soliciting, initiating or encouraging tender offers competing with the Offer and, more generally, any alternative transaction with any person other than the Bidder; and
• and, more generally, entered into reciprocal cooperation undertakings customary in tender offers.

The Company has also undertaken to conduct the Group’s activities in the normal course of business between the signing of the cooperation agreement and the end of the Offer period.

Investment Agreement

On July 31^st, 2024, the members of the Consortium entered into an investment agreement in order to set out the main terms and conditions of the Offer and of the investment by its members for the purposes of the Offer (the “Investment Agreement“). Under the terms of the Investment Agreement, the Bidder and the members of the Consortium declared that they were acting in concert within the meaning of article L.  233-10 of the French Commercial Code and EurobioNext, a shareholder and director of the Company, has undertaken to contribute to the Bidder all of the shares of the Company that it holds (i.e. 34.04% of the share capital and theoretical voting rights of the Company³), by way of a contribution in kind with effect before the first settlement-delivery of the Offer if the Offer is successful.

Commitments to contribute to the Offer

On June 7^th, 2024, Echiumbio Holding B.V., holding 9.42% of the Company’s share capital to date, committed to IK Partners to tender the Company shares it holds to the Offer. In addition, under the terms of the Investment Agreement, Mr. Denis Fortier, Mr. Hervé Duchesne de Lamotte and Ms. Cathie Marsais have undertaken to tender the shares of the Company that they hold, which together represent 0.12% of the Company’s share capital.

These commitments may be revoked if a competing tender offer has been declared compliant by the AMF and opened at a price higher than the Offer Price, and if the Bidder does not file a competing improved tender offer.

Conditions precedent and timetable for the Offer

It is expected that the draft Offer document and draft reply document will be filed at the end of September by the Bidder and the Company respectively, so that the Offer can be submitted to the AMF in October 2024.

In accordance with applicable regulations, the filing of the Offer is subject to the appointment of an investment services provider, approved to carry out underwriting activities and guaranteeing the content and irrevocable nature of the commitments made by the Bidder, and to the issue by the AMF of an opinion of conformity of the Offer.

The Offer is subject to the condition precedent of the authorization from the European Commission under merger control regulations, it being specified that the Bidder reserves the right to waive this condition, and the opening of the Offer is subject to the prior authorization from the competent foreign investments control authorities in France and Italy.

Subject to the issue by the AMF of its opinion on the conformity of the Offer, the Offer will be opened in the days following the Bidder’s obtaining the necessary authorizations for the control of foreign investments in France.

In addition to the mandatory expiry threshold provided for in Article 231-9, I, 1° of the AMF’s General Regulation, the Offer will be subject to a waiver threshold pursuant to Article 231-9, II of the AMF’s General Regulation, allowing the Bidder to withdraw the Offer if less than 66.66% of the Company’s shares and theoretical voting rights are tendered at the end of the Offer.

Pre-offer period

This press release opens a pre-offer period within the meaning of the AMF General Regulation.

Disclaimer:

This press release has been prepared for information purposes only. It does not constitute a public offering. The distribution of this press release may be subject to specific regulations or restrictions in certain countries. This press release is not intended for persons subject to such restrictions, either directly or indirectly. This press release is not for release, publication or distribution, directly or indirectly, in the United States of America or in any other jurisdiction in which such release, publication or distribution is unlawful or subject to any specific procedures or requirements. Accordingly, persons in possession of this press release are required to inform themselves about and to observe any local restrictions that may apply. Failure to comply with legal restrictions may constitute a violation of applicable securities laws and regulations in any of these countries. Eurobio Scientific S.A. and the members of the Consortium accept no liability for any breach by any person of such restrictions.

About IK Partners
IK Partners (“IK”) is a European private equity firm focused on investments in the Benelux, DACH, France, Nordics and the UK. Since 1989, IK has raised more than €17 billion of capital and invested in over 190 European companies. IK supports companies with strong underlying potential, partnering with management teams and investors to create robust, well-positioned businesses with excellent long-term prospects. For more information, visit www.ikpartners.com

About Nextstage AM
NextStage AM is an independent management company based in Paris, approved by the AMF, that has cultivated since its creation in 2002 an “entrepreneur-investor” philosophy, and is one of the pioneers and leaders of innovative and patient growth capital in France. NextStage AM has developed, step by step, a multi-strategy Private Equity platform that represents in terms of assets, directly and indirectly, €8 billion of AUM at the end of June 2024. NextStage AM invests in a limited number of SMEs and ETIs (81 portfolio companies as of 30/06/2024), French and European, innovative and growing, to which it provides entrepreneurial expertise as an investor, and strong operational support throughout their transformation. NextStage AM provides long-term support to these SMEs and ETIs involved in smart health, environmental innovation, and digital transformation. NextStage AM gives them the means to accelerate their development and their innovative capacity to become “Champions” on their markets, both in France and internationally, through organic and/or external growth.
https://www.nextstage-am.com

1 Volume-weighted average price over 60 trading days until July 30^th, 2024.
2 Mr. Denis Fortier (CEO), Ms. Cathie Marsais (Deputy CEO), Mr. Olivier Bosc (Deputy CEO), Mr. Jean-Michel Carle-Grandmougin (Deputy CEO and Director) and Mr. Hervé Duchesne de Lamotte (Director)
3 Based on the total number of shares and theoretical voting rights in the Company determined in accordance with article 223-11 of the AMF’s General Regulations as at July 31^st, 2024, i.e. 10,248,871 ordinary shares corresponding to 10,248,871 theoretical voting rights.

Attachment

• PR_Eurobio Scientific_Projet_Offre_EN_3107